Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Other users also viewed these articles

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies Ruben Burgos-Vargas, Mario Cardiel, Daniel Xibillèc), Cèc)sar Pacheco-Tena, Virginia Pascual-Ramos, Carlos Abud-Mendoza, Ehab Mahgoub, Mahboob Rahman, Haiyun Fan, Ricardo Rojo, Erika García, Karina Santana

10.1016/j.reumae.2017.04.009

Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries J.M. Reyes, M.V. Gutierrez, H. Madariaga, W. Otero, R. Guzman, J. Izquierdo, M. Abello, P. Velez, D. Castillo, D. Ponce de Leon, T. Lukic, L. Amador

10.1016/j.reumae.2023.02.006

Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report Salomé Garcia, Georgina Terroso, Elisabete Martins, Sofia Pimenta, Lúcia Costa, Miguel Bernardes

10.1016/j.reumae.2021.06.006